Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Francisco Perez Clavijo

Podiatrist, Foot & Ankle Surgery Doral, FL Doctor of Podiatric Medicine

NPI 1366447625 CMS profile 107465

8339 Nw 12Th St, Doral, FL 33126

Open in the dashboard

General payments

$13,262

170 records reported · program years 2019–2025

Research payments

$1,750

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$129,609 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Francisco Perez Clavijo of Doral, FL is reported in the CMS Open Payments database as having received $13,262 across 170 general payments and $1,750 in research payments paid to them. Separately, studies naming them as principal investigator received $129,609 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $965 11
2024 General $783 12
2023 General $805 21
2022 General $1,806 40
2021 General $1,645 22
2020 General $3,068 16
2020 Research $1,750 1
2019 General $4,190 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Francisco Perez Clavijo
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Francisco Perez Clavijo were reported at $965. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Francisco Perez Clavijo Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $4,190 $389 $118–$1,406 $163
2020 $3,068 $191 $62–$691 $114
2021 $1,645 $329 $104–$1,341 $132
2022 $1,806 $419 $125–$1,611 $149
2023 $805 $377 $128–$1,164 $160
2024 $783 $394 $134–$1,168 $164
2025 $965 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $2,882 39 payments
  2. Royal Biologics $2,445 7 payments
  3. Musculoskeletal Transplant Foundation Inc. $1,838 17 payments
  4. Smith+Nephew, Inc. $1,454 33 payments
  5. AbbVie, Inc. $1,164 38 payments
  6. Shockwave Medical, Inc $1,087 8 payments
  7. Anika Therapeutics, Inc. $873 3 payments
  8. Wright Medical Technology, Inc. $248 2 payments
  9. Osiris Therapeutics Inc. $238 4 payments
  10. Innovation Technologies Inc $135 1 payment
  11. Other $898 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,143 160 payments
  2. Consulting Fee $1,600 2 payments
  3. Travel and Lodging $1,356 4 payments
  4. Entertainment $163 4 payments
Products named General payments · program years 2019–2025
  1. CryoCord $1,496 5 payments
  2. DALVANCE $1,164 38 payments
  3. Stravix $1,069 18 payments
  4. Puraply $981 17 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $949 7 payments
  6. Tactoset $873 3 payments
  7. Fibrinet $800 1 payment
  8. GRAFIX $581 9 payments
  9. GrafixPL $580 8 payments
  10. PuraPly AM $461 1 payment
  11. Other $4,817 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Integra LifeSciences Corporation $1,750 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

408

Median for Podiatry: 160

Drug cost

$13,594

Median for Podiatry: $2,368

Branded share of claims

10.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 14 $4,832
Ciclopirox Generic 141 $3,165
Clotrimazole Generic 60 $2,508
Ammonium Lactate Generic 69 $1,198
Ketoconazole Generic 70 $1,128
Nystatin Generic 11 $412
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 13 $124
Ciclopirox Ciclopirox Olamine Brand 16 $114
Mupirocin Generic 14 $113

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$205,053

Medicare's payments for the services billed

Medicare patients

780

Average age 83

Services billed

3,916

458 women, 322 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 64%
Depression 61%
Arthritis 58%
Diabetes 55%
Ischemic heart disease 55%
Heart failure 47%
Chronic kidney disease 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $34
$34 — —
TEFLARO
  • AbbVie, Inc. $34
$34 — —
AVYCAZ
  • AbbVie, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

171 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record